US$14 b is AU$160 per share for Neuren.I think you are right that similar deal would be reasonable for Neuren in not too distant future.
Analysts estimated $2 billion peak sales potential for Karuna drug for Schizophrenia if approved.
Trof peak sales likely $1 billion now and NNZ-2591 for 4 current Ph 2 indications been said to be 5x market size ie $5 billion. Which is 2.5x for Karuna drug.They just completed Ph 3 of course, and we are still Ph 2. But if you add a 60% discount for that you'd end up same place as Karuna.
I personally believe any takeover will be over 100. And if Neuren keep pushing it could be $150 or more potentially.
Bristol Myers to acquire Karuna for $14Billion, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$15.17 |
Change
-0.220(1.43%) |
Mkt cap ! $1.888B | |||
| Open | High | Low | Value | Volume |
| $15.45 | $15.45 | $15.03 | $6.517M | 428.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 7052 | $15.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.20 | 199 | 1 |
View Market Depth
| Last trade - 16.10pm 21/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |